Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Phase Ⅲ Clinical Trial of an Investigative 24-valent Pneumococcal Polysaccharide Conjugate Vaccine

11 november 2026 bijgewerkt door: Reinovax Biologics Co., LTD

Multicenter, Randomized, Double-Blind, Active-Controlled Phase III Trial to Evaluate the Immunogenicity and Safety of a 24-Valent Pneumococcal Conjugate Vaccine (PCV24, RZ700) Following Vaccination in Adults Aged 18 Years and Older

A phase III clinical trial of a 24-valent pneumococcal conjugate vaccine (PCV24) developed by Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older.The study's objective is to evaluate the safety and immunogenicity of PCV24. The trial is a multicenter, randomized, double-blind and active-controlled phase III clinical trial.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

A Phase Ⅲ clinical trial of the 24-valent pneumococcal conjugate vaccine (PCV24) developed by Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older. The study's objective is to evaluate the safety and immunogenicity of PCV24. The active control vaccine is a 23-valent pneumococcal polysaccharide vaccine (PPSV23) produced by Merck & Co.A total of 1,260 participants will be enrolled, including 756 participants aged 65-74 years, who will be randomized 1:1 to receive one dose of PCV24 or PPSV23, and 84 participants aged 75 years and older, who will be randomized 1:1 to receive one dose of PCV24 or PPSV23. In addition, 420 participants aged 18-64 years will receive one dose of PCV24.

Studietype

Ingrijpend

Inschrijving (Geschat)

1260

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Tao Huang, Bachelor
  • Telefoonnummer: 86+15084736658
  • E-mail: ymlc01@hnedc.com

Studie Locaties

      • Shanghai, China
        • Shanghai Center for Disease Control and Prevention
        • Contact:
    • Hunan
      • Changsha, Hunan, China
        • Hunan Center for Disease Control and Prevention
        • Contact:
    • Yunan
      • Baoshan, Yunan, China, 678000
        • Baoshan Second People's Hospital
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

1)Aged 18 years and older, able to provide valid legal identification; 2)Capable of understanding the clinical trial procedures, voluntarily agreeing to participate, and signing the informed consent form; 3)Willing and able to comply with the requirements of the clinical trial protocol and to attend all scheduled visits; 4) Male participants and female participants of childbearing potential agreeing to use effective contraception within 6 months after vaccination (effective contraceptive measures include: oral contraceptives, injectable or implanted contraceptives, sustained-release topical contraceptives, hormone patches, intrauterine device (IUD), sterilization, abstinence, and condoms (for males)); the rhythm method, coitus interruptus, and emergency contraception are not acceptable contraceptive measures; 5) Axillary temperature ≤37.0°C on the day of enrollment. Exclusion Criteria:

  1. Previous vaccination with any pneumococcal vaccine, or a history of invasive pneumococcal disease caused by Streptococcus pneumoniae within 3 years before enrollment;
  2. History of any severe allergic reaction, such as anaphylactic shock, allergic laryngeal edema, angioneurotic edema, dyspnea, severe urticaria, allergic purpura, or local allergic necrotizing reaction (Arthus reaction); or a history of thrombocytopenic purpura; or known allergy to any component of the investigational vaccine (aluminum phosphate adjuvant, phenol, sodium chloride, succinic acid, polysorbate 80, or water for injection);
  3. Lactating or pregnant women, or women of childbearing potential planning to become pregnant during the study period; women of childbearing potential who have not used effective contraception from the end of their last menstrual cycle until enrollment; or women of childbearing potential with a positive urine pregnancy test at enrollment (sensitivity 25 mIU/mL for β-hCG);
  4. Diagnosed with congenital or acquired immunodeficiency; or other diseases affecting immune function (such as asplenia, functional asplenia, and asplenia or splenectomy due to any cause).
  5. Long-term (continuous ≥14 days) use of immunosuppressants or other immunomodulatory drugs within 3 months before enrollment or planned during the study period [e.g., systemic corticosteroids ≥14 days at a dose of ≥2 mg/kg/day or ≥20 mg/day prednisone or equivalent; topical use is permitted (e.g., ointments, eye drops, inhalers, or nasal sprays), provided the dose does not exceed the recommended dosage in the package insert];
  6. Severe cardiovascular disease, such as myocardial infarction (acute onset within 6 months before signing the informed consent form), cardio-cerebrovascular syndrome, severe arrhythmia, unstable angina, or poorly controlled arrhythmia;
  7. Systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg measured at the screening physical examination on site; for participants with a history of hypertension, enrollment is permitted only if confirmed by inquiry that blood pressure has been stable over the past 3 months and there have been no obvious cardio-cerebrovascular disease-related symptoms in the past 2 weeks;
  8. Receipt of blood or blood-related products, or immunoglobulin within 3 months before enrollment (except hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin);
  9. Vaccination with any other inactivated vaccine within 7 days before vaccination, or with any live attenuated vaccine within 14 days before vaccination;
  10. Acute illness within 3 days before vaccination, or acute exacerbation of a chronic disease, or use of antipyretic/analgesic drugs (excluding medications used to control pre-existing conditions that, in the investigator's judgment, would not affect the evaluation of study results, such as aspirin used for antiplatelet aggregation) or anti-allergic drugs;
  11. Active tuberculosis, active viral hepatitis, or HIV infection; or other active infectious diseases that, in the judgment of the investigator, may affect the safety of vaccination or interfere with the assessment of immunogenicity;
  12. Severe neurological diseases (e.g., uncontrolled epilepsy), or a history of psychiatric disorders affecting normal behavior, or a family history of such diseases with a hereditary tendency;
  13. Diagnosed thrombocytopenia, any coagulation disorder, or receiving anticoagulant therapy, or other conditions contraindicating intramuscular injection;
  14. Severe chronic diseases or chronic diseases in an uncontrolled progressive stage (e.g., uncontrolled diabetes, severe hepatic or renal disease), excluding a history of cured or stable, well-controlled tumors (except malignant tumors);
  15. Use of another investigational or unregistered product (drug or vaccine) within 1 month before enrollment, or current participation in another clinical trial, or planned participation in another clinical trial during the study period;
  16. Any other condition that, in the opinion of the investigator, may interfere with the evaluation of the study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Experimental group 1

378 participants aged 65-74 years will be randomly assigned to receive Reinovax's PCV24. The route of administration is intramuscular injection into the deltoid muscle of the upper arm. The immunization schedule is 1 dose.

Prevention of pneumococcal infection caused from 24 pneumococcal serotypes (1, 2, 3, 4 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) using a novel PCV24 prepared with Reinovax's non-toxic dual carrier protein system. Administration of one dose at 0.5 mL

Actieve vergelijker: Active control group 1

378 participants aged 65-74 years will be randomly assigned to receive PPSV23. The route of administration is intramuscular injection into the lateral deltoid muscle of the upper arm. The immunization schedule is 1 dose.

One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and 33F polysaccharides.

Andere namen:
  • Pneumovax 23
Experimenteel: Experimental group 2

42 participants aged 75 years and older will be randomly assigned to receive Reinovax's PCV24. The route of administration is intramuscular injection into the deltoid muscle of the upper arm. The immunization schedule is 1 dose.

Prevention of pneumococcal infection caused from 24 pneumococcal serotypes (1, 2, 3, 4 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) using a novel PCV24 prepared with Reinovax's non-toxic dual carrier protein system. Administration of one dose at 0.5 mL

Actieve vergelijker: Active control group 2

42 participants aged 75 years and older will be randomly assigned to receive PPSV23. The route of administration is intramuscular injection into the lateral deltoid muscle of the upper arm. The immunization schedule is 1 dose.

One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and 33F polysaccharides.

Andere namen:
  • Pneumovax 23
Experimenteel: Experimental group 3

420 participants aged 18-64 years will receive Reinovax's PCV24. The route of administration is intramuscular injection into the deltoid muscle of the upper arm. The immunization schedule is 1 dose.

Prevention of pneumococcal infection caused from 24 pneumococcal serotypes (1, 2, 3, 4 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) using a novel PCV24 prepared with Reinovax's non-toxic dual carrier protein system. Administration of one dose at 0.5 mL

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Functional antibody titers measured by the multiplexed opsonophagocytic assay (MOPA).
Tijdsspanne: 0~30 days after vaccination

The geometric mean titers (GMTs) of 24 vaccine serotype-specific MOPA antibodies at 0 days and 30 days after vaccination in participants aged 65 years and older, measured by the multiplexed opsonophagocytic assay (MOPA).

0~30 days after vaccination
Proportional participants with the MOPA titer rise of 4-fold or higher
Tijdsspanne: 0~30 days after vaccination

The percentage of participants aged 65 years and older whose MOPA antibody titers show a 4-fold or greater increase from the pre-immunization baseline at 30 days after vaccination, for each of the 24 vaccine serotypes.

0~30 days after vaccination
Functional antibody titers measured by the multiplexed opsonophagocytic assay (MOPA).
Tijdsspanne: 0~30 days after vaccination

The geometric mean titers (GMTs) of the 24 vaccine serotype-specific MOPA antibodies at 0 day and 30 days after vaccination in participants aged 18-64 years, measured by the multiplexed opsonophagocytic assay (MOPA).

0~30 days after vaccination
Incidence of adverse events
Tijdsspanne: 0-30 minutes after vaccination

The incidence of any local and systemic adverse events occurring within 30 minutes after vaccination.

0-30 minutes after vaccination
Incidence of solicited adverse events
Tijdsspanne: 0-7 days after vaccination

The incidence of solicited adverse events occurring within 7 days after vaccination.

0-7 days after vaccination
Incidence of unsolicited adverse events
Tijdsspanne: 0-30 days after vaccination

The incidence of unsolicited adverse events occurring within 30 days after vaccination.

0-30 days after vaccination
Incidence of serious adverse events (SAE)
Tijdsspanne: 0-6 months after vaccination

The incidence of serious adverse events (SAE) occurring within 6 months after vaccination.

0-6 months after vaccination

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Seropositivity rate as measured using MOPA
Tijdsspanne: 0~30 days after vaccination

The percentage of participants aged 65 years and older with MOPA antibody titers ≥1:8 for each of the 24 vaccine serotypes, detected by MOPA 30 days after immunization. Unit of measure: percentage of participants.

0~30 days after vaccination
Increase rate of as measured using MOPA
Tijdsspanne: 0~30 days after vaccination

The percentage of participants aged 65 years and older whose MOPA antibody titer shows a 2-fold or greater increase from the pre-immunization baseline at 30 days after immunization, for each of the 24 vaccine serotypes. Unit of measure: percentage of participants.

0~30 days after vaccination
The geometric mean fold rise (GMFR) of MOPA antibody titers
Tijdsspanne: 0~30 days after vaccination

The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific MOPA antibody titers from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 65 years and older.

0~30 days after vaccination
Seropositivity rate of IgG antibodies
Tijdsspanne: 0~30 days after vaccination

The percentage of participants aged 65 years and older with IgG geometric mean concentration (GMC) ≥0.35 µg/mL for each of the 24 vaccine serotypes, detected by ELISA 30 days after immunization. Unit of measure: percentage of participants.

0~30 days after vaccination
Positive conversion rate of IgG antibodies
Tijdsspanne: 0~30 days after vaccination

The percentage of participants aged 65 years and older whose IgG antibody concentration shows a 2-fold or greater increase (positive conversion) from the pre-immunization baseline at 30 days after immunization, for each of the 24 vaccine serotypes. Unit of measure: percentage of participants.

0~30 days after vaccination
The IgG geometric mean concentration (GMC) of each serotype
Tijdsspanne: 0~30 days after vaccination

The geometric mean concentration (GMC) of 24 vaccine serotype-specific IgG antibodies detected by ELISA 30 days after immunization in participants aged 65 years and older.

0~30 days after vaccination
The geometric mean fold rise (GMFR) of IgG antibodies
Tijdsspanne: 0~30 days after vaccination

The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific IgG antibody concentration from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 65 years and older.

0~30 days after vaccination
Seropositivity rate of multiplexed opsonophagocytic assay (MOPA) antibodies
Tijdsspanne: 0~30 days after vaccination

The percentage of participants aged 18-64 years with MOPA antibody titer ≥1:8 for each of the 24 vaccine serotypes, detected by MOPA 30 days after immunization. Unit of measure: percentage of participants.

0~30 days after vaccination
Increase rate of multiplexed opsonophagocytic assay (MOPA) antibodies
Tijdsspanne: 0~30 days after vaccination

The percentage of participants aged 18-64 years whose MOPA antibody titer shows a 2-fold or greater increase from the pre-immunization baseline (2-fold increase rate), and the percentage whose MOPA antibody titer shows a 4-fold or greater increase from the pre-immunization baseline (4-fold increase rate), at 30 days after immunization for each of the 24 vaccine serotypes. Unit of measure: percentage of participants.

0~30 days after vaccination
The geometric mean fold rise (GMFR) of multiplexed opsonophagocytic assay (MOPA) antibodies
Tijdsspanne: 0~30 days after vaccination

The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific MOPA antibody titer from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 18-64 years.

0~30 days after vaccination
Seropositivity rate of IgG antibodies
Tijdsspanne: 0~30 days after vaccination

The percentage of participants aged 18-64 years with IgG antibody concentration ≥0.35 µg/mL for each of the 24 vaccine serotypes, detected by ELISA 30 days after immunization. Unit of measure: percentage of participants.

0~30 days after vaccination
Positive conversion rate of IgG antibodies
Tijdsspanne: 0~30 days after vaccination

The percentage of participants aged 18-64 years whose IgG antibody concentration shows a 2-fold or greater increase (positive conversion) from the pre-immunization baseline at 30 days after immunization, for each of the 24 vaccine serotypes. Unit of measure: percentage of participants.

0~30 days after vaccination
The geometric mean concentration (GMC) of specific IgG antibodies
Tijdsspanne: 0~30 days after vaccination

The geometric mean concentration (GMC) of 24 vaccine serotype-specific IgG antibodies detected by ELISA 30 days after immunization in participants aged 18-64 years.

0~30 days after vaccination
The geometric mean fold rise (GMFR) of specific IgG antibodies
Tijdsspanne: 0~30 days after vaccination

The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific IgG antibody concentration from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 18-64 years.

0~30 days after vaccination

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

24 november 2026

Primaire voltooiing (Geschat)

1 oktober 2027

Studie voltooiing (Geschat)

1 oktober 2027

Studieregistratiedata

Eerst ingediend

27 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

11 november 2026

Eerst geplaatst (Werkelijk)

17 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

17 november 2026

Laatste update ingediend die voldeed aan QC-criteria

11 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • RNCVCT7A003

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .